During a Case-Based Roundtable® event, John N. Allan, MD, discussed the addition of anti-CD20 antibody and the use of MRD ...

GOG286B reported efficacy findings and new exploratory outcomes on the combination of metformin, paclictaxel, and carboplatin ...

John Seymour, MBBS, FRACP, PhD, explains why BCL-2 was considered an undruggable target for so long and what led to the development of effective BCL-2 inhibitors.

Findings from a phase 1 trial demonstrate that silmitasertib shows potential for the treatment of patients with advanced basal cell carcinoma.

The FDA cleared the investigational new drug application for ALX2004, with phase 1 trials expected to begin in mid-2025 for ...

Dual checkpoint inhibitors led to longer overall survival in patients with high-risk endometrial cancer who displayed ...

Paige PanCancer Detect has gained FDA breakthrough device designation, a first for AI identifying diverse cancers across ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

A panelist discusses how steroid therapy remains the cornerstone of acute graft-vs-host disease (GVHD) treatment, with treatment protocols typically starting with prednisone at doses ranging from 1 to ...